804 related articles for article (PubMed ID: 24182623)
1. [Diagnostic and prognostic power of biomarkers to improve the management of community acquired pneumonia in the emergency department].
Julián-Jiménez A; Timón Zapata J; Laserna Mendieta EJ; Sicilia-Bravo I; Palomo-de Los Reyes MJ; Cabezas-Martínez A; Laín-Terés N; Estebaran-Martín J; Lozano-Ancín A; Cuena-Boy R
Enferm Infecc Microbiol Clin; 2014 Apr; 32(4):225-35. PubMed ID: 24182623
[TBL] [Abstract][Full Text] [Related]
2. [Ability of procalcitonin to predict bacteremia in patients with community acquired pneumonia].
Julián-Jiménez A; Timón Zapata J; Laserna Mendieta EJ; Parejo Miguez R; Flores Chacartegui M; Gallardo Schall P
Med Clin (Barc); 2014 Apr; 142(7):285-92. PubMed ID: 24120103
[TBL] [Abstract][Full Text] [Related]
3. Usefulness and prognostic value of biomarkers in patients with community-acquired pneumonia in the emergency department.
Julián-Jiménez A; González Del Castillo J; Candel FJ
Med Clin (Barc); 2017 Jun; 148(11):501-510. PubMed ID: 28391994
[TBL] [Abstract][Full Text] [Related]
4. Pro-adrenomedullin to predict severity and outcome in community-acquired pneumonia [ISRCTN04176397].
Christ-Crain M; Morgenthaler NG; Stolz D; Müller C; Bingisser R; Harbarth S; Tamm M; Struck J; Bergmann A; Müller B
Crit Care; 2006; 10(3):R96. PubMed ID: 16805922
[TBL] [Abstract][Full Text] [Related]
5. [Prognostic and stratified value of adrenomedullin in community acquired pneumonia patients in emergency department].
Chen Y; Li C
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2014 Feb; 26(2):115-9. PubMed ID: 24524403
[TBL] [Abstract][Full Text] [Related]
6. Prognostic power of proadrenomedullin in community-acquired pneumonia is independent of aetiology.
Bello S; Lasierra AB; Mincholé E; Fandos S; Ruiz MA; Vera E; de Pablo F; Ferrer M; Menendez R; Torres A
Eur Respir J; 2012 May; 39(5):1144-55. PubMed ID: 22075489
[TBL] [Abstract][Full Text] [Related]
7. Proadrenomedullin, a useful tool for risk stratification in high Pneumonia Severity Index score community acquired pneumonia.
Courtais C; Kuster N; Dupuy AM; Folschveiller M; Jreige R; Bargnoux AS; Guiot J; Lefebvre S; Cristol JP; Sebbane M
Am J Emerg Med; 2013 Jan; 31(1):215-21. PubMed ID: 23000327
[TBL] [Abstract][Full Text] [Related]
8. Usefulness of midregional proadrenomedullin to predict poor outcome in patients with community acquired pneumonia.
Gordo-Remartínez S; Calderón-Moreno M; Fernández-Herranz J; Castuera-Gil A; Gallego-Alonso-Colmenares M; Puertas-López C; Nuevo-González JA; Sánchez-Sendín D; García-Gámiz M; Sevillano-Fernández JA; Álvarez-Sala LA; Andueza-Lillo JA; de Miguel-Yanes JM
PLoS One; 2015; 10(6):e0125212. PubMed ID: 26030588
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of mid-regional pro-adrenomedullin (MR-proADM) in patients with community-acquired pneumonia: a systematic review and meta-analysis.
Liu D; Xie L; Zhao H; Liu X; Cao J
BMC Infect Dis; 2016 May; 16():232. PubMed ID: 27230573
[TBL] [Abstract][Full Text] [Related]
10. Prognostic performance of MR-pro-adrenomedullin in patients with community acquired pneumonia in the Emergency Department compared to clinical severity scores PSI and CURB.
Legramante JM; Mastropasqua M; Susi B; Porzio O; Mazza M; Miranda Agrippino G; D Agostini C; Brandi A; Giovagnoli G; Di Lecce VN; Bernardini S; Minieri M
PLoS One; 2017; 12(11):e0187702. PubMed ID: 29161297
[TBL] [Abstract][Full Text] [Related]
11. Performance of pro-adrenomedullin for identifying adverse outcomes in community-acquired pneumonia.
España PP; Capelastegui A; Mar C; Bilbao A; Quintana JM; Diez R; Esteban C; Bereciartua E; Unanue U; Uranga A
J Infect; 2015 May; 70(5):457-66. PubMed ID: 25499199
[TBL] [Abstract][Full Text] [Related]
12. Prognostic power of biomarkers for short-term mortality in the elderly patients seen in Emergency Departments due to infections.
Julián-Jiménez A; Yañez MC; González-Del Castillo J; Salido-Mota M; Mora-Ordoñez B; Arranz-Nieto MJ; Chanovas-Borras MR; Llopis-Roca F; Mòdol-Deltell JM; Muñoz G;
Enferm Infecc Microbiol Clin (Engl Ed); 2019 Jan; 37(1):11-18. PubMed ID: 29289378
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of proadrenomedullin in severe sepsis and septic shock patients with community-acquired pneumonia.
Suberviola B; Castellanos-Ortega A; Llorca J; Ortiz F; Iglesias D; Prieto B
Swiss Med Wkly; 2012; 142():w13542. PubMed ID: 22430899
[TBL] [Abstract][Full Text] [Related]
14. Correlation of inflammatory and cardiovascular biomarkers with pneumonia severity scores.
Lacoma A; Bas A; Tudela P; Giménez M; Mòdol JM; Pérez M; Ausina V; Dominguez J; Prat-Aymerich C
Enferm Infecc Microbiol Clin; 2014 Mar; 32(3):140-6. PubMed ID: 24054971
[TBL] [Abstract][Full Text] [Related]
15. Red blood cell distribution width [RDW] and long-term mortality after community-acquired pneumonia. A comparison with proadrenomedullin.
Bello S; Fandos S; Lasierra AB; Mincholé E; Panadero C; Simon AL; Gavin O; De Pablo F; Menendez R; Torres A
Respir Med; 2015 Sep; 109(9):1193-206. PubMed ID: 26205553
[TBL] [Abstract][Full Text] [Related]
16. Ability of procalcitonin to differentiate true bacteraemia from contaminated blood cultures in an emergency department.
Zafar Iqbal-Mirza S; Serrano Romero de Ávila V; Estévez-González R; Rodríguez-González D; Heredero-Gálvez E; Julián-Jiménez A
Enferm Infecc Microbiol Clin (Engl Ed); 2019 Nov; 37(9):560-568. PubMed ID: 30904350
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular and inflammatory biomarkers to predict short- and long-term survival in community-acquired pneumonia: Results from the German Competence Network, CAPNETZ.
Krüger S; Ewig S; Giersdorf S; Hartmann O; Suttorp N; Welte T;
Am J Respir Crit Care Med; 2010 Dec; 182(11):1426-34. PubMed ID: 20639437
[TBL] [Abstract][Full Text] [Related]
18. Risk stratification and prediction value of procalcitonin and clinical severity scores for community-acquired pneumonia in ED.
Zhou H; Guo S; Lan T; Ma S; Zhang F; Zhao Z
Am J Emerg Med; 2018 Dec; 36(12):2155-2160. PubMed ID: 29691103
[TBL] [Abstract][Full Text] [Related]
19. Biomarkers improve mortality prediction by prognostic scales in community-acquired pneumonia.
Menéndez R; Martínez R; Reyes S; Mensa J; Filella X; Marcos MA; Martínez A; Esquinas C; Ramirez P; Torres A
Thorax; 2009 Jul; 64(7):587-91. PubMed ID: 19131448
[TBL] [Abstract][Full Text] [Related]
20. Thirty and ninety days mortality predictive value of admission and in-hospital procalcitonin and mid-regional pro-adrenomedullin testing in patients with dyspnea. Results from the VERyfing DYspnea trial.
Travaglino F; Russo V; De Berardinis B; Numeroso F; Catania P; Cervellin G; Nigra SG; Geraci F; Bressan MA; Guerrini S; Cavazza M; Folli C; Monzani V; Battista S; Mengozzi G; Noto P; Carpinteri G; Semplicini A; Stella F; Ingrassia S; Moscatelli P; Giuntini P; Salerno G; Cardelli P; Di Somma S
Am J Emerg Med; 2014 Apr; 32(4):334-41. PubMed ID: 24559907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
